Citations 21
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
Copelan, Edward A. , Hamilton, Betty K. , Avalos, Belinda R. , Ahn, Kwang Woo , Bolwell, Brian J., Zhu, Xiaochun , Aljurf, Mahmoud , Bredeson, Christopher , Cahn, Jean‐Yves , Costa, Luciano J. , Hale, Gregory A., Halter, Joerg , Inamoto, Yoshihiro , Kamble, Rammurti T., Litzow, Mark R. , Loren, Alison W. , Marks, David I. , Olavarría, Eduardo, Sabloff, Mitchell , Seftel, Matthew D. , Schouten, Harry C. , Üstün, Celalettin , Waller, Edmund K. , Weisdorf, Daniel J. , Wirk, Baldeep , Horowitz, Mary M. , Arora, Mukta , Cortes, Jörge E. , Kalaycio, Matt, Saber, Wael , Halter, Jörg , Besien, Koen van , Lima, Marcos de , Gale, Robert Peter , Hamadani, Mehdi , Roy, Vivek , Savani, Bipin N. , Szer, Jeff , Maziarz, Richard Thomas , Waller, Edmund K , Weisdorf, Dan , Cortes, Jorge , Costa, Luciano J , Sabloff, Mitchell
Blood | September 25, 2013 | Volume: 122 | Issue: 24 | Pages: 3863-3870
Key Points In combination with cyclophosphamide, intravenous busulfan is associated with better leukemia-free and overall survival in AML than TBI.